Novel Sutureless Scleral Fixated IOL for Inadequate or Absent Capsular Support

Table 2

Results.

	Total	PPV group	Non PPV group
Preoperative logMAR BCVA	0.85 ± 0.59; (range 0.05–2.3)	1.02 ± 0.60; (range 0.05–1.8)	0.83 ± 0.61; (range 0.15–2.3)
1-month postoperative logMAR BCVA	0.44 ± 0.30; (range 0.05–1)	0.65 ± 0.37; (range 0.15–1)	0.37 ± 0.35; (range 0.05–0.95)
6 months postoperative logMAR BCVA	0.36 ± 0.34; (range 0.05–1)	0.47 ± 0.30; (range 0.05–1)	0.32 ± 0.33; (range 0.05–0.95)
12 months postoperative logMAR BCVA	0.35 ± 0.32; (range 0.05–1)	0.50 ± 0.30; (range 0.05–1)	0.33 ± 0.32; (range 0.05–0.95)
24 months postoperative logMAR BCVA	0.33 ± 0.32; (range 0.05–0.9)	0.45 ± 0.27; (range 0.05–0.9)	0.30 ± 0.31; (range 0.05–0.6)
Endothelial cell count	Preoperative	2472 ± 202 cells/mm^2	2553 ± 205 cells/mm^2
	Postoperative	2387 ± 197 cells/mm^2	2453 ± 200 cells/mm^2
Indication	Dislocated PC IOL (40.7%)
	AC IOL complication (11.1%)
	Subluxated traumatic cataract (18.5%)
	Subluxated nontraumatic cataract (18.5%)
	Aphakia (11.1%)